This study investigated the utility of three VEGF gene variants, previously shown to affect VEGF expression, and baseline plasma VEGF-A levels as prognostic markers in a well-characterized cohort of acute coronary syndromes patients (ACS) over prolonged follow up [19–22]. This evidence concerns the gene VEGFA and acute coronary syndrome.